205 related articles for article (PubMed ID: 19323788)
1. Recommendations on biosimilar low-molecular-weight heparins.
Harenberg J; Kakkar A; Bergqvist D; Barrowcliffe T; Casu B; Fareed J; Mismetti P; Ofosu FA; Raake W; Samama M; Schulman S;
J Thromb Haemost; 2009 Jul; 7(7):1222-5. PubMed ID: 19323788
[TBL] [Abstract][Full Text] [Related]
2. Differences of present recommendations and guidelines for generic low-molecular-weight heparins: is there room for harmonization.
Harenberg J
Clin Appl Thromb Hemost; 2011; 17(6):E158-64. PubMed ID: 21406409
[TBL] [Abstract][Full Text] [Related]
3. Overview on guidelines and recommendations for generic low-molecular-weight heparins.
Harenberg J
Thromb Res; 2011 Feb; 127 Suppl 3():S100-4. PubMed ID: 21262425
[TBL] [Abstract][Full Text] [Related]
4. A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins.
Ofosu FA
Thromb Haemost; 2012 Feb; 107(2):201-14. PubMed ID: 22234312
[TBL] [Abstract][Full Text] [Related]
5. Low-molecular-weight heparin.
Wolf H
Med Clin North Am; 1994 May; 78(3):733-43. PubMed ID: 8170267
[TBL] [Abstract][Full Text] [Related]
6. Market entry of biosimilar low-molecular-weight heparins in Europe: opportunities and challenges.
Simoens S; Huys I
Semin Thromb Hemost; 2013 Apr; 39(3):250-7. PubMed ID: 23235959
[TBL] [Abstract][Full Text] [Related]
7. Low-molecular-weight heparins for the prevention and treatment of venous thromboembolism.
Ornstein DL; Hong-Dice YG; Papini JR
Mil Med; 2001 Jul; 166(7):593-601. PubMed ID: 11469031
[TBL] [Abstract][Full Text] [Related]
8. Low-molecular-weight heparin for the prevention and treatment of venous thromboembolism in pregnancy.
McColl MD; Greer IA
Curr Opin Pulm Med; 2004 Sep; 10(5):371-5. PubMed ID: 15316434
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM
Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711
[TBL] [Abstract][Full Text] [Related]
10. Venous thromboembolism prevention with LMWHs in medical and orthopedic surgery patients.
Deitelzweig SB; Vanscoy GJ; Niccolai CS; Rihn TL
Ann Pharmacother; 2003 Mar; 37(3):402-11. PubMed ID: 12639173
[TBL] [Abstract][Full Text] [Related]
11. Low molecular weight heparins differ substantially: impact on developing biosimilar drugs.
Walenga JM; Jackson CM; Kessler CM
Semin Thromb Hemost; 2011 Apr; 37(3):322-7. PubMed ID: 21455866
[TBL] [Abstract][Full Text] [Related]
12. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.
Adiguzel C; Jeske WP; Hoppensteadt D; Walenga JM; Bansal V; Fareed J
Clin Appl Thromb Hemost; 2009; 15(2):137-44. PubMed ID: 19357102
[TBL] [Abstract][Full Text] [Related]
13. Update of the recommendations on biosimilar low-molecular-weight heparins from the Scientific Subcommittee on Control of Anticoagulation of the International Society on Thrombosis and Haemostasis.
Harenberg J; Walenga J; Torri G; Dahl OE; Drouet L; Fareed J;
J Thromb Haemost; 2013 Jul; 11(7):1421-5. PubMed ID: 23615078
[No Abstract] [Full Text] [Related]
14. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
15. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
[TBL] [Abstract][Full Text] [Related]
16. An update on heparins at the beginning of the new millennium.
Fareed J; Hoppensteadt DA; Bick RL
Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight heparin in the treatment of venous thromboembolism.
Hull RD; Pineo GF
Semin Thromb Hemost; 2000; 26 Suppl 1():61-7. PubMed ID: 11011809
[TBL] [Abstract][Full Text] [Related]
18. [State of the art: low-molecular-weight heparin and beyond].
Cimminiello C; Casali G; Vitali L
Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):61-5. PubMed ID: 11253343
[TBL] [Abstract][Full Text] [Related]
19. Low molecular weight heparins for venous thromboembolism.
Drug Ther Bull; 1998 Apr; 36(4):25-9. PubMed ID: 9684414
[TBL] [Abstract][Full Text] [Related]
20. Low-molecular-weight heparins in thrombosis and cancer: emerging links.
Mousa SA
Cardiovasc Drug Rev; 2004; 22(2):121-34. PubMed ID: 15179449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
